Table 1. Characteristics of Sample A (all and by 10% weight gain one year after transplantation).
| Characteristic | All | wg≥10%* | wg<10%* | p-value # |
|---|---|---|---|---|
| n = 995 | n = 204 | n = 673 | ||
| Recipient age at transplantation (years), median (range) | 54 (18–79) | 51 (18–73) | 55 (18–79) | 0.0001 |
| Recipient men (%) | 66.0 | 56.8 | 68.9 | 0.001 |
| Period of follow up (months), median (range) | 12 (0–48) | 12 (0–48) | 12 (0–48) | 0.55 |
| Living donor (%) | 27.1 | 27.9 | 29.6 | 0.6 |
| Donor age (years), median (range) | 53 (1–86) | 50 (1–80) | 53 (1–86) | 0.04 |
| Transplanted organ (%) | ||||
| Kidney | 62.4 | 61.3 | 67.2 | <0.001 |
| Liver | 15.9 | 10.3 | 14.7 | |
| Lung | 9.5 | 14.7 | 7.8 | |
| Heart | 6.5 | 11.3 | 4.6 | |
| Multi-organ transplantation | 4.1 | 2.5 | 4.5 | |
| Before transplant | ||||
| BMI (kg/m2), median (range) | 24.6 (13.7–41.2) | 23.1 (14.9–37.4) | 24.9 (14.3–41.2) | 0.0001 |
| Overweight (25 kg/m2 ≤ BMI >30 kg/m2), % | 30.7 | 23.0 | 32.5 | <0.001 |
| Obese (BMI ≥ 30 kg/m2), % | 15.3 | 9.3 | 16.8 | |
| HDL (mmol/L), median (range) | 1.2 (0.01–8) | 1.2 (0.1–4.1) | 1.2 (0.09–8) | 0.7 |
| LDL (mmol/L), median (range) | 2.2 (0.06–10.02) | 2.2 (0.1–7.1) | 2.2 (0.08–10.0) | 0.3 |
| Cholesterol (mmol/L), median (range) | 4.2 (0.3–11.7) | 4.0 (0.3–9.9) | 4.2 (0.8–11.7) | 0.2 |
| At 12 months after transplant | ||||
| BMI (kg/m2), median (range) | 25.2 (15.3–44.6) | 27.1 (18.8–44.6) | 24.7 (15.3–44.3) | 0.0001 |
| Overweight (25 kg/m2 ≤ BMI >30 kg/m2), % | 34.7 | 39.0 | 33.0 | <0.001 |
| Obese (BMI ≥ 30 kg/m2), % | 17.0 | 27.0 | 14.0 | |
| HDL (mmol/L), median (range) | 3.5 | 1.3 (0.5–4.1) | 1.3 (0.2–7.0) | 0.08 |
| LDL (mmol/L), median (range) | 1.3 (0.21–7) | 2.6 (0.8–5.8) | 2.6 (0.3–8.7) | 0.8 |
| Cholesterol (mmol/L), median (range) | 2.6 (0.3–8.7) | 5.0 (2.3–9.2) | 4.8 (1.7–12.0) | 0.01 |
| Incidence of NODAT (%)$ | 27.1 | 25.9 | 28.1 | 0.6 |
| CMV serostatus (%) | ||||
| Recipient CMV infection (R+) | 57.1 | 21.8 | 23.7 | 0.9 |
| Donor CMV infection (D+) | 53.0 | 20.8 | 20.6 | |
| Recipient and Donor CMV infection (R+D+) | 32.6 | 33.2 | 33.1 | |
| Calcineurin inhibitors (%) | ||||
| TAC | 45.1 | 42.2 | 48.6 | 0.3 |
| CSA | 19.6 | 21.1 | 19.6 | |
| None | 35.2 | 36.8 | 31.8 |
wg: weight gain, CMV: Cytomegalovirus, TAC: Tacrolimus, CSA: Cyclosporine, NODAT: New Onset Diabetes After Transplant
# comparison between wg≥10% and wg<10%
*at 12 months after transplantation, missing n = 118
$NODAT was diagnosed if patients were taking an antidiabetic treatment after transplantation or if diabetes was reported in their case report forms. NODAT excluded those patients with diabetes previous to transplant